In addition, MC3324, a dual inhibitor of LSD1 and KDM6A/B, increased H3K4me2 and H3K27me3, followed by growth arrest and enhanced apoptosis of prostate cancer cells, downregulation of AR, and impairment of cellular metabolism. Here, AR is linked to prostate carcinoma.